Abstract

OP8 A New Complement Inhibitor: Impact of Ravulizumab on Eculizumab and Future Biosimilars Use, and Role of Paris Public Hospitals (AP-HP)

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call